Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail by GBIResearch

VIEWS: 63 PAGES: 72

Leading business intelligence provider, GBI Research, has released its latest research report, entitled: “Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail”. The report provides insights into the liver cancer therapeutics market in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan, with market forecasts until 2018. It provides in-depth analysis of the major marketed products, as well as insights into the liver cancer therapeutics R&D pipeline. The report also gives in-depth analysis of the unmet needs, drivers and barriers that affect the markets in these countries. Additionally, it discusses the global pipeline for all the liver cancer molecules across various stages of development.

More Info
									Liver Cancer Therapeutics Market to 2018
Nexavar, the Only Approved Targeted Therapy for Advanced Disease,
Continues to Dominate as Other Late Stage Trials Fail
GBI Research Report Guidance




                                              GBI Research Report Guidance
                                              ·     The report starts with an executive summary of the key points influencing liver cancer therapeutics in
                                                    the top seven markets.
                                              ·     Chapter two summarizes the scope of the report and contains the report guidance.
                                              ·     Chapter three gives an overview of liver cancer, covering the symptoms, diagnosis and treatment
                                                    options available for the disease.
                                              ·     Chapter four gives an overview of the liver cancer therapeutics market, its drivers and barriers and the
                                                    recent developments in the top seven markets.
                                              ·     Chapter five estimates the market size of the US, the UK, France, Germany, Spain, Italy and Japan, and
                                                    gives forecasts to 2018. A key analysis of the treatment usage pattern is also discussed.
                                              ·     Chapter six gives details on the current pipeline analysis of the liver cancer market. The section also
                                                    contains detailed analysis of the most promising pipeline products.
                                              ·     Chapter seven analyzes the top companies operating in the liver cancer market and includes
                                                    benchmarking and detailed profiles of the leading companies.
                                              ·     Chapter eight discusses in detail the strategic consolidations that have taken place within the global
                                                    liver cancer therapeutics market, looking at key licensing agreements.




  © GBI Research. This is a licensed product and is not to be photocopied                                                    GBIHC287MR / Published DEC 2012
                                                                                                                                                      Page 2
Liver Cancer Therapeutics Market to 2018 - Executive Summary




                                              Liver Cancer Therapeutics Market to 2018 - Executive Summary
                                              The Liver Cancer Therapeutics Market is Forecast to Grow at a CAGR of 8.1% from 2011 to 2018

      The liver cancer therapeutics           The liver cancer therapeutics market in the top seven markets (the US, the UK, Germany, France, Spain, Italy
      market in the top seven                 and Japan) was estimated at $374.3m in 2011, having grown at a Compound Annual Growth Rate (CAGR) of
      markets (the US, the UK,                21.7% from 2004. Growth was driven by an increase in the patient volume and the Annual Cost of Therapy
      Germany, France, Spain,                 (ACT) per patient, which was itself due to the approval of Nexavar (sorafenib) in the US and Europe. The
      Italy and Japan) was                    market is forecast to reach $644.3m by 2018 at a CAGR of 8.1% from 2011. The anticipated launch of Eli
      estimated at $374.3m in                 Lilly's ramucirumab (IMC-1121B), a monoclonal Antibody (mAb) in 2014; Celsion Corporation's ThermoDox
      2011, having grown at a                 in 2014; and PrevOnco in 2015 will drive market growth.
      Compound Annual Growth
                                                Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2004-2018
      Rate (CAGR) of 21.7% from
      2004
                                                                   800

                                                                         CAGR (2004–2011): 21.7%
                                                                         CAGR (2011–2018): 8.1%




                                                                   600
                                                    Revenue ($m)




                                                                   400




                                                                   200




                                                                     0
                                                                              2004                    2011                           2018


                                                Source: GBI Research




                                              Newer Techniques are Being Studied for Treating Liver Cancer
                                              Hepatocellular Carcinoma (HCC) is usually detected late as symptoms tend to appear in the advanced stages
                                              of the disease. As a result, most patients have a poor prognosis. Poor diagnosis measures also affect the
                                              patient volume available for HCC treatment. New treatment options have recently been considered for
                                              treating HCC, and doctors are looking at advances in different types of neoadjuvant (before surgery) and
                                              adjuvant (after surgery) therapies that might help to increase survival rates. Chemotherapy, ablation,
                                              embolization and radiation therapy are examples of important types of neoadjuvant therapy.
                                              New drugs are being developed that work differently from standard chemotherapy drugs, by targeting
                                              specific parts of cancer cells or their surrounding environment. Nexavar, which works by hindering new
                                              blood vessel and thereby tumor growth, is being studied for use in the early stages of cancer. Additionally, a
                                              newer approach to treatment is the use of a virus known as JX-594, the same virus that was used to make
                                              the smallpox vaccine, but that has been altered so that it infects mainly cancer cells by causing them to die
                                              or make proteins that result in them being attacked by the body’s immune system, leaving normal cells
                                              unaffected.




  © GBI Research. This is a licensed product and is not to be photocopied                                                    GBIHC287MR / Published DEC 2012
                                                                                                                                                      Page 3
Liver Cancer Therapeutics Market to 2018 - Executive Summary




      There are currently 80                  Hepatocellular Carcinoma Pipeline has 80 Molecules in Various Phases of Development
      molecules in various stages
                                              Companies and research institutions are actively pursuing R&D activities for HCC treatment, and activity is
      of development, of which the
                                              expected to remain high during the 2011-2018 period. There are currently 80 molecules in various stages of
      majority are in Phase II
                                              development, of which the majority are in Phase II (25%) and Preclinical (26%). Late-stage molecules (Phase
      (25%) and Preclinical (26%)
                                              III and Phase II/III) account for 17%, while Phase I/II and Phase I constitute 29%. Discovery constitutes the
                                              remaining 3% of the HCC pipeline.

                                                Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012

                                                                                                     Discovery
                                                                                                        3%                 Phase III
                                                                                                                             16%

                                                                            Preclinical
                                                                               26%                                                     Phase II/III
                                                                                                                                          1%




                                                                                                           N=80
                                                                                                                                         Phase II
                                                                                                                                          25%




                                                                                      Phase I
                                                                                       23%                           Phase I/II
                                                                                                                       6%


                                                Source: GBI Research Proprietary Deals Database [accessed December 17, 2012]




                                              However, in recent late-stage clinical trials (such as BRISK-FL, PS), one of the most promising molecules,
                                              Bristol-Myers Squibb’s (BMS’) brivanib, was announced to be ineffective at meeting its primary endpoint.
                                              Additionally, Pfizer discontinued a Phase III study of Sutent (sunitinib malate) for HCC in 2010 due to a high
                                              incidence of serious adverse effects and Sutent’s inability to prove its superiority over Nexavar.
                                              Weak Competition in the Liver Cancer Therapeutics Market
                                              The competitive landscape in the liver cancer therapeutics market is weak with only Miripla (Japan) and
                                              Nexavar (US and Europe) being approved for the treatment of HCC. Prior to Nexavar’s approval in 2007,
                                              doxorubicin, cisplatin, 5-fluorouracil, gemcitabine and their combination regimens were the most
                                              commonly used off-label chemotherapeutic agents, despite a low response rate in clinical studies and lack
                                              of evidence relating to overall survival impact. Although a number of molecules are in late-stage clinical
                                              trials, they are not expected to be approved until 2014 and 2015. Bayer and Dainippon Sumitomo Pharma
                                              (DSP) are currently the only companies whose products have received approvals.




  © GBI Research. This is a licensed product and is not to be photocopied                                                                     GBIHC287MR / Published DEC 2012
                                                                                                                                                                       Page 4
Table of Contents




                                              1         Table of Contents
                                              1   Table of Contents ........................................................................................................................................ 5
                                                  1.1      List of Tables .................................................................................................................................... 7
                                                  1.2      List of Figures................................................................................................................................... 8
                                              2   Liver Cancer Therapeutics Market to 2018 - Introduction .......................................................................... 9
                                              3   Liver Cancer Therapeutics Market to 2018 - Overview ............................................................................. 10
                                                  3.1      Introduction................................................................................................................................... 10
                                                      3.1.1      Benign Tumor ........................................................................................................................ 10
                                                      3.1.2      Primary Liver Cancer ............................................................................................................. 10
                                                      3.1.3      Secondary Liver Cancer ......................................................................................................... 10
                                                  3.2      Symptoms ...................................................................................................................................... 11
                                                  3.3      Diagnosis ....................................................................................................................................... 11
                                                      3.3.1      Laboratory Tests.................................................................................................................... 11
                                                      3.3.2      Imaging Tests ........................................................................................................................ 11
                                                      3.3.3      Others.................................................................................................................................... 12
                                                  3.4      Treatment Options ........................................................................................................................ 12
                                                      3.4.1      Surgery .................................................................................................................................. 13
                                                      3.4.2      Non-surgical .......................................................................................................................... 13
                                                      3.4.3      General Treatment Algorithm ............................................................................................... 15
                                                      3.4.4      Treatment by Stage ............................................................................................................... 16
                                                      3.4.5      New Technologies in Treatment ............................................................................................ 18
                                              4   Liver Cancer Therapeutics Market to 2018 - Market Characterization and Forecasts .............................. 19
                                                  4.1      Revenue ......................................................................................................................................... 19
                                                  4.2      Annual Cost of Therapy ................................................................................................................. 22
                                                  4.3      Marketed Products ........................................................................................................................ 23
                                                      4.3.1      Nexavar ................................................................................................................................. 23
                                                      4.3.2      Miripla ................................................................................................................................... 25
                                                  4.4      Treatment Usage Pattern .............................................................................................................. 27
                                                      4.4.1      Prevalence Population ........................................................................................................... 28
                                                      4.4.2      Diagnosed Population ........................................................................................................... 28
                                                      4.4.3      Prescription Population ......................................................................................................... 28
                                                  4.5      Drivers and Barriers of Liver Cancer Therapeutics Market ............................................................ 28
                                                      4.5.1      Drivers ................................................................................................................................... 28
                                                      4.5.2      Barriers .................................................................................................................................. 29
                                              5   Liver Cancer Therapeutics Market to 2018 - Geographical Landscape ..................................................... 30
                                                  5.1      US .................................................................................................................................................. 30
                                                      5.1.1      Introduction ........................................................................................................................... 30
                                                      5.1.2      Revenue ................................................................................................................................. 30
                                                      5.1.3      Cost of Therapy ..................................................................................................................... 32
                                                      5.1.4      Treatment Usage Pattern ...................................................................................................... 33
                                                  5.2      Top Five European Countries ........................................................................................................ 34
                                                      5.2.1      Introduction ........................................................................................................................... 34
                                                      5.2.2      Revenue ................................................................................................................................. 34
                                                      5.2.3      Cost of Therapy ..................................................................................................................... 36
                                                      5.2.4      Treatment Usage Pattern ...................................................................................................... 37
                                                  5.3      Japan ............................................................................................................................................. 38
                                                      5.3.1      Introduction ........................................................................................................................... 38
                                                      5.3.2      Revenue ................................................................................................................................. 38
                                                      5.3.3      Cost of Therapy ..................................................................................................................... 39
                                                      5.3.4      Treatment Usage Pattern ...................................................................................................... 40
                                              6   Liver Cancer Therapeutics Market to 2018 - Pipeline Analysis ................................................................. 41


  © GBI Research. This is a licensed product and is not to be photocopied                                                                                            GBIHC287MR / Published DEC 2012
                                                                                                                                                                                              Page 5
Table of Contents




                                                  6.1    Introduction................................................................................................................................... 41
                                                  6.2    R&D Product Pipeline by Stage of Development ........................................................................... 43
                                                    6.2.1      Phase III ................................................................................................................................. 43
                                                    6.2.2      Phase II/III ............................................................................................................................. 44
                                                    6.2.3      Phase II .................................................................................................................................. 44
                                                    6.2.4      Phase I/II ............................................................................................................................... 45
                                                    6.2.5      Phase I ................................................................................................................................... 46
                                                    6.2.6      Pre-Clinical ............................................................................................................................ 47
                                                    6.2.7      Discovery ............................................................................................................................... 47
                                                6.3      Profiles of Promising Molecules .................................................................................................... 48
                                                    6.3.1      PrevOnco ............................................................................................................................... 48
                                                    6.3.2      Ramucirumab ........................................................................................................................ 48
                                                    6.3.3      ThermoDox ............................................................................................................................ 49
                                                    6.3.4      Afinitor .................................................................................................................................. 50
                                              7 Liver Cancer Therapeutics Market to 2018 - Competitive Landscape ....................................................... 51
                                                7.1      Bayer ............................................................................................................................................. 51
                                                7.2      Dainippon Sumitomo Pharma ....................................................................................................... 52
                                              8 Liver Cancer Therapeutics Market to 2018 - Strategic Consolidations...................................................... 53
                                                8.1      Introduction................................................................................................................................... 53
                                                8.2      Deals by Geography....................................................................................................................... 54
                                                8.3      Deals by Year ................................................................................................................................. 55
                                                8.4      Mergers and Acquisition Deals ...................................................................................................... 56
                                                    8.4.1      Overview ............................................................................................................................... 56
                                                    8.4.2      Profiles of Major M&A Deals ................................................................................................. 57
                                                8.5      Licensing Agreements.................................................................................................................... 58
                                                    8.5.1      Overview ............................................................................................................................... 58
                                                    8.5.2      Profiles of Major Licensing Agreements ................................................................................ 60
                                                8.6      Co-Development Agreements ....................................................................................................... 62
                                                    8.6.1      Overview ............................................................................................................................... 62
                                                    8.6.2      Profiles of Major Co-Development Agreements .................................................................... 63
                                              9 Liver Cancer Therapeutics Market to 2018 - Appendix ............................................................................. 64
                                                9.1      Market Definitions......................................................................................................................... 64
                                                9.2      Abbreviations ................................................................................................................................ 64
                                                9.3      Bibliography .................................................................................................................................. 66
                                                9.4      Research Methodology ................................................................................................................. 67
                                                    9.4.1      Coverage ............................................................................................................................... 67
                                                    9.4.2      Secondary Research .............................................................................................................. 68
                                                    9.4.3      Primary Research .................................................................................................................. 68
                                                9.5      Therapeutic Landscape .................................................................................................................. 69
                                                    9.5.2      Market Size by Geography .................................................................................................... 70
                                                9.6      Geographical Landscape ................................................................................................................ 71
                                                9.7      Pipeline Analysis ............................................................................................................................ 71
                                                9.8      Competitive Landscape ................................................................................................................. 72
                                                    9.8.1      Expert Panel Validation ......................................................................................................... 72
                                                9.9      Contact Us ..................................................................................................................................... 72
                                                9.10 Disclaimer ...................................................................................................................................... 72




  © GBI Research. This is a licensed product and is not to be photocopied                                                                                         GBIHC287MR / Published DEC 2012
                                                                                                                                                                                           Page 6
Table of Contents




                                              1.1      List of Tables
                                              Table 1:     Liver Cancer Therapeutics Market, Top Seven Markets, Revenue ($m), 2004-2011 .................... 19
                                              Table 2:     Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2011-2018.... 19
                                              Table 3:     Liver Cancer Therapeutics Market, Top Seven Markets, Revenue by Geography ($m), 2004-2011
                                                           ...................................................................................................................................................... 20
                                              Table 4:     Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m),
                                                           2011-2018 .................................................................................................................................... 21
                                              Table 5:     Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2011 22
                                              Table 6:     Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2011-2018 22
                                              Table 7:     Liver Cancer Therapeutics Market to 2018, Nexavar, Clinical Trial Results .................................. 23
                                              Table 8:     Liver Cancer Therapeutics Market, Nexavar, Adverse Reactions Reported in Clinical Trial ......... 24
                                              Table 9:     Liver Cancer Therapeutics Market, Nexavar, Approval History .................................................... 25
                                              Table 10:    Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2004-
                                                           2011.............................................................................................................................................. 27
                                              Table 11:    Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2011-
                                                           2018.............................................................................................................................................. 27
                                              Table 12:    Liver Cancer Therapeutics Market, US, Revenue ($m), 2004-2011 .............................................. 30
                                              Table 13:    Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2011-2018 .............................. 31
                                              Table 14:    Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2011 .......................... 32
                                              Table 15:    Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2011-2018 .......................... 32
                                              Table 16:    Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2004-2011.................. 33
                                              Table 17:    Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2011-2018.................. 33
                                              Table 18:    Liver Cancer Therapeutics Market, Top Five European Countries, Revenue ($m), 2004-2011 .... 35
                                              Table 19:    Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2011-
                                                           2018.............................................................................................................................................. 35
                                              Table 20:    Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy
                                                           ($), 2004-2011 .............................................................................................................................. 36
                                              Table 21:    Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy
                                                           ($), 2011-2018 .............................................................................................................................. 36
                                              Table 22:    Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern
                                                           (‘000), 2004-2011 ......................................................................................................................... 37
                                              Table 23:    Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern
                                                           (‘000), 2011-2018 ......................................................................................................................... 37
                                              Table 24:    Liver Cancer Therapeutics Market, Japan, Revenue ($m), 2004-2011 ......................................... 38
                                              Table 25:    Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2011-2018 ........................... 39
                                              Table 26:    Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2011 ..................... 39
                                              Table 27:    Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2018 ..................... 39
                                              Table 28:    Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2004-2011 ............. 40
                                              Table 29:    Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2011-2018 ............. 40
                                              Table 30:    Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012.. 42
                                              Table 31:    Liver Cancer Therapeutics Market, Global, Phase III Pipeline ...................................................... 43
                                              Table 32:    Liver Cancer Therapeutics Market, Global, Phase II/III Pipeline ................................................... 44
                                              Table 33:    Liver Cancer Therapeutics Market, Global, Phase II Pipeline ....................................................... 44
                                              Table 34:    Liver Cancer Therapeutics Market, Global, Phase I/II Pipeline ..................................................... 45
                                              Table 35:    Liver Cancer Therapeutics Market, Global, Phase I Pipeline ........................................................ 46
                                              Table 36:    Liver Cancer Therapeutics Market, Global, Preclinical, 2012 ....................................................... 47
                                              Table 37:    Liver Cancer Therapeutics Market, Global, Discovery, 2012 ........................................................ 47
                                              Table 38:    Liver Cancer Therapeutics Market, Global, Bayer AG, Pharmaceutical Brands, 2012 .................. 51
                                              Table 39:    Liver Cancer Therapeutics Market, Global, Dainippon Sumitomo Pharma, Pharmaceutical
                                                           Brands, 2012 ................................................................................................................................. 52
                                              Table 40:    Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012 ................. 53
                                              Table 41:    Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012............................... 54
                                              Table 42:    Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012 ......................................... 55
                                              Table 43:    Liver Cancer Therapeutics Market, Global, Major M&A Deals, 2007-2012 .................................. 56
                                              Table 44:    Liver Cancer Therapeutics Market, Global, Major Licensing Agreement Deals, 2007-2012 ......... 58
                                              Table 45:    Liver Cancer Therapeutics Market, Global, Major Co-Development Deals, 2007-2012 ............... 62




  © GBI Research. This is a licensed product and is not to be photocopied                                                                                           GBIHC287MR / Published DEC 2012
                                                                                                                                                                                             Page 7
Table of Contents




                                              1.2      List of Figures
                                              Figure 1:    Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Treatment Options, 2012
                                                           ...................................................................................................................................................... 12
                    
								
To top